FDA approves Leukine for Acute Radiation Syndrome | Blood supply model could help nation prepare for emergencies

FDA approves Leukine for Acute Radiation Syndrome | Blood supply model could help nation prepare for emergencies

FDA Approves Leukine for Acute Radiation Syndrome A new BARDA-supported medical countermeasure, Leukine, has been approved by FDA to treat adult and pediatric patients with certain radiological or nuclear injuries after a disaster. Leukine, developed by Sanofi and manufactured by Partner Therapeutics, is effective when given up to two days after exposure to ionizing radiation. BARDA has supported 35 FDA approvals to address chemical, biological, radiological, and nuclear threats; pandemic influenza; and emerging infectious diseases.

Learn More